Brief: Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System
03/04/2025 22:03
April 3 (Reuters) - Sangamo Therapeutics Inc SGMO.O: SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM SANGAMO THERAPEUTICS INC: SANGAMO TO RECEIVE AN $18 MILLION UPFRONT LICENSE FEE SANGAMO THERAPEUTICS INC: ELIGIBLE TO EARN UP TO $1.4 BILLION IN ADDITIONAL LICENSED TARGET FEES AND MILESTONE PAYMENTS SANGAMO: AGREEMENT GRANTS LILLY RIGHTS TO EMPLOY CO'S NOVEL PROPRIETARY CAPSID, STAC-BBB, FOR UP TO 5 POTENTIAL DISEASE TARGETS Source text: ID:nBw1y4wTga Further company coverage: SGMO.O ((Reuters.Briefs@thomsonreuters.com;))